A Five-Year Review of Soft Tissue Tumors with Intermediate Malignant Potential and Soft Tissue Sarcomas in a Tertiary Hospital: University of the Philippines – Philippine General Hospital
Keywords:soft tissue, sarcoma, Philippines
Objective. Describe the epidemiology of Soft Tissue Tumors with Intermediate Malignant Potential (STTI) and Soft Tissue Sarcomas (STS) diagnosed in Philippine General Hospital, Department of Laboratories, Section of Surgical Pathology, from years 2014 to 2018.
Methodology. We utilized a descriptive, retrospective, cross-sectional study design and involved all newly-diagnosed cases of STTI and STS that fit the specified set of inclusion and exclusion criteria.
Results. Out of 1896 cases of probable STTI and STS on initial screening, 680 cases (36%) were included in the study. Of the 1216 excluded cases, 815 (43%) needed ancillary diagnostic workup for definitive classification. Sarcoma, Not Otherwise Specified (n=149; 21.9%; 95% CI [18.80, 25.02]) was the most common diagnosis, followed by gastrointestinal stromal tumor (n=91; 13.4%; 95% CI [10.82, 15.94]) and leiomyosarcoma (n=62; 9.1%; 95% CI [6.95%, 11.28%]). Median age was 47 years, with a slight female predominance (n=371; 55%; 0.83 male to female ratio). The extremities (n=244, 36%) were the most frequent site.
Conclusion. The significant amount of cases excluded in the study may account for the differences of distribution. Despite the increased immunohistochemistry tests available, there is still an apparent inaccessibility to ancillary diagnostic methods that are necessary in the diagnosis of STTI and STS.
2. Howlader N, Noone AM, Krapcho M, et al, eds. SEER cancer statistics review, 1975-2016. National Cancer Institute. Bethesda, MD. https://seer.cancer.gov/csr/1975_2016/ based on November 2018 SEER data submission, posted to the SEER web site. Accessed September 1, 2020.
3. Fletcher CD, Bridge JA, Hogendoorn PC, Mertens F. WHO classification of tumours of soft tissue and bone, 4th ed. Lyon: International Agency for Research on Cancer; 2013.
4. Mastrangelo GE, Coindre JM, Ducimetière F, et al. Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions. Cancer. 2020;118(21):5339-48. https://pubmed.ncbi.nlm.nih.gov/22517534. https://doi.org/10.1002/cncr.27555.
5. Laurini JA, Cooper K, Fletcher CDM, et al. Protocol for the examination of resection specimens from patients with soft tissue tumors. College of American Pathologists. 2020. https://documents.cap.org/protocols/cp-other-softtissue-resection-20-4020.pdf. Accessed September 1, 2020.
6. Ngan R, Wang E, Porter D, at al. Soft-tissue sarcomas in the Asia-Pacific Region: a systematic review. Asian Pac J Cancer Prev. 2013;14(11):6821-32. https://pubmed.ncbi.nlm.nih.gov/24377612. https://doi.org/10.7314/apjcp.2013.14.11.6821.
7. Ngelangel CA, Wang EH. Cancer and the Philippine Cancer Control Program. Jpn J Clin Oncol. 2002;32 Suppl:S52-61. https://pubmed.ncbi.nlm.nih.gov/11959878. https://doi.org/10.1093/jjco/hye126.
8. The WHO classification of tumours editorial board, ed. WHO classification of tumours of soft tissue and bone, 5th ed. Lyon: International Agency for Research on Cancer; 2020.
9. Gage MM, Nagarajan N, Ruck JM, et al. Sarcomas in the United States: recent trends and a call for improved staging. Oncotarget. 2019;10(25):2462–74. https://pubmed.ncbi.nlm.nih.gov/ 31069009. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497437. https://doi.org/10.18632/oncotarget.26809.
How to Cite
The Philippine Journal of Pathology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on works made open access at http://philippinejournalofpathology.org